Table 1.
Characteristics of the subjects in IBDGC-1 and IBDGC-2.
| IBDGC-1 | IBDGC-2 | |||
|---|---|---|---|---|
| Control Subjects (n = 97) | CD Patients (n = 97) | Control Subjects (n = 199) | CD Patients(n = 199) | |
| Age at recruitment, y | ||||
| Range | 19-70 | 19-70 | 16-76 | 16-87 |
| Median | 39 | 39 | 35 | 37 |
| IQR | 28-50 | 27-50 | 26-50 | 28-46 |
| Ethnicity | ||||
| White non-Jewish | 84 (86.6) | 83 (85.6) | 156 (78.4) | 156 (78.4) |
| Jewish | 8 (8.2) | 9 (9.3) | 43 (21.6) | 43 (21.6) |
| Black/African American | 5 (5.2) | 5 (5.1) | 0 (0) | 0 (0) |
| Female | 50 (51.5) | 52 (53.6) | 111 (55.8) | 111 (55.8) |
| Surgery history | ||||
| Yes | — | 86 (88.7) | — | 96 (48.2) |
| No | — | 10 (10.3) | — | 103 (51.8) |
| Missing | — | 1 (1) | — | 0 (0) |
| Tobacco use | ||||
| Smoker | 9 (9.3) | 21 (21.7) | 21 (10.5) | 47 (23.6) |
| Ex-smoker | 13 (13.4) | 8 (8.2) | 30 (15.1) | 20 (10.1) |
| Nonsmoker | 74 (76.3) | 67 (69.1) | 145 (72.9) | 129 (64.8) |
| Missing | 1 (1) | 1 (1) | 3 (1.5) | 3 (1.5) |
| Montreal classification | ||||
| Disease behavior | ||||
| Inflammatory (B1) | — | 0 (0) | — | 106 (53.3) |
| Stricturing (B2) | — | 51 (52.6) | — | 52 (26.1) |
| Penetrating (B3) | — | 46 (47.4) | — | 41 (20.6) |
| Disease location | ||||
| Ileal (L1) | — | 30 (31) | — | 53 (26.6) |
| Colorectal (L2) | — | 8 (8.2) | — | 47 (23.6) |
| Ileocolonic (L3) | — | 58 (59.8) | — | 99 (49.8) |
| Missing | — | 1 (1) | — | 0 (0) |
Values are n (%), unless otherwise indicated. This table presents the demographic and clinical phenotypes of the CD patients and healthy control subjects selected from the National Institute of Diabetes and Digestive and Kidney Diseases IBDGC Repository and retained into the final post–quality-control datasets for IBDGC-1 and IBDGC-2 phases of the current study.
Abbreviations: CD, Crohn’s disease; IBDGC, National Institute of Diabetes and Digestive and Kidney Diseases IBD Genetics Consortium; IQR, interquartile range.